Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats - PubMed (original) (raw)
Comparative Study
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats
Jian-She Yang et al. J Neuroimmunol. 2004 Nov.
Abstract
The new orally active drug laquinimod (ABR-215062) was evaluated in experimental autoimmune encephalomyelitis (EAE) in the Lewis rat. EAE shares important immunological and clinical features with multiple sclerosis (MS). Doses of 16, 1.6 and 0.16 mg/kg/day laquinimod dose-dependently inhibited disease and showed better disease inhibitory effects as compared to roquinimex (Linomide). Furthermore, laquinimod inhibited the inflammation of both CD4+ T cells and macrophages into central nervous tissues, i.e. the spinal cord. It also changed the cytokine balance in favour of TH2/TH3 cytokines IL-4, IL-10 and TGF-beta. Laquinimod therefore represents a new orally active immunoregulatory drug without general immunosuppressive properties with a potential for the treatment of severe autoimmune diseases like MS.
Similar articles
- Th1 and Th2 cytokine immunomodulation by gangliosides in experimental autoimmune encephalomyelitis.
Monteiro de Castro G, Eduarda Zanin M, Ventura-Oliveira D, Aparecida Vilella C, Ashimine R, de Lima Zollner R. Monteiro de Castro G, et al. Cytokine. 2004 May 21;26(4):155-63. doi: 10.1016/j.cyto.2004.02.009. Cytokine. 2004. PMID: 15149632 - Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
Liu W, Li WM, Gao C, Sun NL. Liu W, et al. J Autoimmun. 2005 Dec;25(4):258-63. doi: 10.1016/j.jaut.2005.06.005. Epub 2005 Oct 19. J Autoimmun. 2005. PMID: 16242301 - Immunosteroid as a regulator for Th1/Th2 balance: its possible role in autoimmune diseases.
Matsuzaki J, Tsuji T, Imazeki I, Ikeda H, Nishimura T. Matsuzaki J, et al. Autoimmunity. 2005 Aug;38(5):369-75. doi: 10.1080/08916930500124122. Autoimmunity. 2005. PMID: 16227152 Review. - Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis.
Kennedy KJ, Karpus WJ. Kennedy KJ, et al. J Clin Immunol. 1999 Sep;19(5):273-9. doi: 10.1023/a:1020535423465. J Clin Immunol. 1999. PMID: 10535603 Review.
Cited by
- What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?
Buzzard KA, Broadley SA, Butzkueven H. Buzzard KA, et al. Int J Mol Sci. 2012 Oct 4;13(10):12665-709. doi: 10.3390/ijms131012665. Int J Mol Sci. 2012. PMID: 23202920 Free PMC article. Review. - Mechanistic Insights, Treatment Paradigms, and Clinical Progress in Neurological Disorders: Current and Future Prospects.
Alkahtani S, Al-Johani NS, Alarifi S. Alkahtani S, et al. Int J Mol Sci. 2023 Jan 10;24(2):1340. doi: 10.3390/ijms24021340. Int J Mol Sci. 2023. PMID: 36674852 Free PMC article. Review. - A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future.
Gholamzad M, Ebtekar M, Ardestani MS, Azimi M, Mahmodi Z, Mousavi MJ, Aslani S. Gholamzad M, et al. Inflamm Res. 2019 Jan;68(1):25-38. doi: 10.1007/s00011-018-1185-0. Epub 2018 Sep 3. Inflamm Res. 2019. PMID: 30178100 Review. - Oral disease-modifying treatments for multiple sclerosis: the story so far.
Kieseier BC, Wiendl H. Kieseier BC, et al. CNS Drugs. 2007;21(6):483-502. doi: 10.2165/00023210-200721060-00005. CNS Drugs. 2007. PMID: 17521228 Review. - Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.
Du Pasquier RA, Pinschewer DD, Merkler D. Du Pasquier RA, et al. CNS Drugs. 2014 Jun;28(6):535-58. doi: 10.1007/s40263-014-0160-8. CNS Drugs. 2014. PMID: 24723124 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials